Inquire Before Buying - India Cancer Treatment Drugs Market Share Analysis 2032

India Cancer Treatment Drugs Market Research Report: Forecast (2026-2032)

By Drug class (Cytotoxic Drugs (Alkylating Agents, Antimetabolites, Others), Targeted Drugs (Monoclonal Antibodies, Others), Immune Checkpoint Inhibitors, Hormonal Agents, Other Dr......ugs), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatment Types), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Cervical Cancer, Hematologic/Blood Cancers, Head & Neck Cancer, Brain & CNS Cancers, Skin Cancer, Others), By Dosage Form (Solid (Tablets, Capsules), Liquid, Injectable, Prefilled Syringes, Others), By End-Users (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and others Read more

Healthcare
Jun 2026
Pages 139
Report Format: PDF, Excel, PPT

India Cancer Treatment Drugs Market Key Takeaways

The India Cancer Treatment Drugs Market is valued at USD 2.88 billion in 2025 and is projected to reach USD 3.12 billion by 2026 and USD 7.12 billion by 2032.
The industry is projected to witness steady growth at a CAGR of 14.73% during 2026–2032.
Targeted Drugs lead the market with 44% market share in 2026.
Breast Cancer dominates the market by cancer type with 19% share.
North India accounts for the largest share of the market, representing approximately 34% of total revenue in 2026.
The market remains moderately fragmented, with the top five companies accounting for approximately 18% of total market share in 2026.

India Cancer Treatment Drugs Market Size & Outlook

The India Cancer Treatment Drugs Market was valued at USD 2.88 billion in 2025 and is projected to grow from USD 3.12 billion in 2026 to USD 7.12 billion by 2032, registering a CAGR of 14.73% during the forecast period.

The market is witnessing robust expansion owing to the increasing prevalence of cancer, growing healthcare expenditure, and rising demand for advanced oncology therapies across the country. Continuous improvements in healthcare infrastructure, greater awareness regarding early diagnosis, and expanding access to specialized cancer treatment facilities are further supporting industry growth.

India continues to experience a significant rise in cancer incidence, driven by population growth, aging demographics, urbanization, lifestyle-related risk factors, and increasing exposure to environmental pollutants. According to the latest estimates from the Indian Council of Medical Research (ICMR), the country reported more than 14 lakh cancer cases in recent years, with breast, oral, cervical, lung, and colorectal cancers representing a substantial share of the overall disease burden. The growing patient pool is creating sustained demand for cancer therapeutics and supportive care medicines across hospitals, specialty clinics, and cancer treatment centers.

The market is also benefiting from rapid advancements in oncology treatment approaches. Increasing adoption of targeted therapies, immunotherapies, precision medicine, monoclonal antibodies, and biosimilars is improving treatment outcomes and expanding therapeutic options for patients. Pharmaceutical companies are investing significantly in oncology research, clinical development, and strategic collaborations to strengthen their cancer drug portfolios. In addition, the growing availability of innovative biologics and combination therapies is accelerating the transition toward more personalized cancer treatment strategies in India.

Looking ahead, favourable government initiatives and expanding cancer-care infrastructure are expected to create substantial growth opportunities for market participants. Such as 217 AMRIT Pharmacies provide oncology medicines at 50–80% lower prices, while PMBJP supplies 289 essential cancer drugs at subsidized rates. These programs support cancer treatment under public healthcare schemes, and investments in tertiary oncology facilities are enhancing treatment accessibility across urban and semi-urban regions.

Furthermore, the increasing focus on domestic manufacturing, affordable oncology drugs, and next-generation cancer therapies is expected to strengthen market penetration. Supported by rising disease burden, technological innovation, and improving healthcare access, the India Cancer Treatment Drugs Industry is anticipated to maintain strong growth momentum through 2032.

India Cancer Treatment Drugs Market Key Indicators

As per Medical Research-National Cancer Registry Programme, the estimated number of cancer cases in India increased from 13.9 lakh in 2020 to 15.3 lakh in 2024, reflecting a steady rise in disease burden. The expanding patient population is driving demand for chemotherapy, targeted therapies, immunotherapies, and supportive oncology drugs across hospitals and specialty cancer centers nationwide.
According to the Union Budget 2025-26, the Government of India announced the establishment of 200 Day Care Cancer Centres during FY2025-26, with a long-term objective of expanding cancer treatment services across district hospitals. The initiative is expected to improve oncology care accessibility in underserved regions, strengthen treatment capacity, and increase utilization of cancer therapeutics across the country.
The Government of India is expanding cancer screening and diagnosis through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) and Ayushman Bharat network. The country has operationalized more than 1.8 lakh Ayushman Arogya Mandirs, supporting large-scale screening, referral, and early detection programs that are expected to increase treatment uptake and demand for oncology medicines.
According to the Department of Pharmaceuticals, the Indian pharmaceutical sector is valued at more than USD 65 billion and is among the world's largest suppliers of generic medicines. Growing domestic manufacturing capabilities, increasing biologics production, and rising investments in specialty pharmaceuticals are supporting the development and availability of affordable oncology drugs across India.

Under Ayushman Bharat-PMJAY, more than 6.8 million cancer treatments worth approximately USD 1.5 billion have been delivered, including over 450,000 targeted therapy treatments valued at around USD 113 million. The large-scale utilization of advanced oncology therapies under a government-funded reimbursement program highlights improving patient access to cancer care across India. Rising treatment coverage and greater affordability are accelerating therapy adoption and strengthening the long-term growth potential of the India Cancer Treatment Drugs Market.

India Cancer Treatment Drugs Market Scope

Category	Segments
By Drug class	Cytotoxic Drugs (Alkylating Agents, Antimetabolites, Others), Targeted Drugs (Monoclonal Antibodies, Others), Immune Checkpoint Inhibitors, Hormonal Agents, Other Drugs
By Treatment Type	Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatment Types
By Cancer Type	Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Cervical Cancer, Hematologic/Blood Cancers, Head & Neck Cancer, Brain & CNS Cancers, Skin Cancer, Others
By Dosage Form	Solid (Tablets, Capsules), Liquid, Injectable, Prefilled Syringes, Others
By End-Users	Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

India Cancer Treatment Drugs Market Drivers

India’s Cancer Treatment Drugs Market is benefiting from expanding screening and early-detection initiatives across the country. As of March 2026, the National NCD Portal reported that 8.73 crore women had been screened for cervical cancer, while the government launched a nationwide HPV vaccination campaign targeting around 1.15 crore girls. These initiatives are improving cancer detection rates and increasing the number of patients entering treatment pathways, thereby supporting sustained demand for oncology drugs and related therapies.

At the same time, India’s oncology care ecosystem is expanding in a way that directly supports drug adoption. The government has approved 19 State Cancer Institutes and 20 Tertiary Care Cancer Centres, while cancer treatment facilities have also been approved in all 22 new AIIMS, strengthening specialized care capacity across the country.

In parallel, the public reimbursement and affordable-medicine network is widening access, with over 200 AB PMJAY packages covering more than 500 oncology-related procedures, 15,057 Jan Aushadhi Kendras, and 222 AMRIT pharmacies offering discounted cancer medicines. This combination of stronger treatment infrastructure and improved affordability is expected to accelerate oncology drug penetration in both public and private care settings.

Market Segmentation
Introduction

2.1. Product Definition

2.2. Research Process

2.3. Assumptions

Executive Summary
India Cancer Treatment Drugs Market Policies, Regulations, and Product Standards
India Cancer Treatment Drugs Market Trends & Developments
India Cancer Treatment Drugs Market Dynamics

6.1. Growth Factors

6.2. Challenges

India Cancer Treatment Drugs Market Hotspot & Opportunities
India Cancer Treatment Drugs Market Outlook, 2022-2032F

8.1. Market Size & Outlook

8.1.1. By Revenues (USD Million)

8.2. Market Share & Outlook

8.2.1. By Drug class- Market Size & Forecast 2022-2032, USD Million

8.2.1.1. Cytotoxic Drugs

8.2.1.1.1. Alkylating Agents

8.2.1.1.2. Antimetabolites

8.2.1.1.3. Others

8.2.1.2. Targeted Drugs

8.2.1.2.1. Monoclonal Antibodies

8.2.1.2.2. Others

8.2.1.3. Immune Checkpoint Inhibitors

8.2.1.4. Hormonal Agents

8.2.1.5. Other Drugs

8.2.2. By Treatment Type- Market Size & Forecast 2022-2032, USD Million

8.2.2.1. Chemotherapy

8.2.2.2. Targeted Therapy

8.2.2.3. Immunotherapy

8.2.2.4. Hormonal Therapy

8.2.2.5. Radiation Therapy

8.2.2.6. Other Treatment Types

8.2.3. By Cancer Type- Market Size & Forecast 2022-2032, USD Million

8.2.3.1. Breast Cancer

8.2.3.2. Lung Cancer

8.2.3.3. Colorectal Cancer

8.2.3.4. Gastrointestinal Cancer

8.2.3.5. Prostate Cancer

8.2.3.6. Cervical Cancer

8.2.3.7. Hematologic/Blood Cancers

8.2.3.8. Head & Neck Cancer

8.2.3.9. Brain & CNS Cancers

8.2.3.10. Skin Cancer

8.2.3.11. Others

8.2.4. By Dosage Form- Market Size & Forecast 2022-2032, USD Million

8.2.4.1. Solid

8.2.4.1.1. Tablets

8.2.4.1.2. Capsules

8.2.4.2. Liquid

8.2.4.3. Injectable

8.2.4.4. Prefilled Syringes

8.2.4.5. Others

8.2.5. By End-Users- Market Size & Forecast 2022-2032, USD Million

8.2.5.1. Hospitals

8.2.5.2. Specialty Clinics

8.2.5.3. Cancer and Radiation Therapy Centers

8.2.6. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million

8.2.6.1. Hospital Pharmacies

8.2.6.2. Retail Pharmacies

8.2.6.3. Online Pharmacies

8.2.7. By Region- Market Size & Forecast 2022-2032, USD Million

8.2.7.1. North

8.2.7.2. South

8.2.7.3. East

8.2.7.4. West

8.2.8. By Company

8.2.8.1. Competition Characteristics

8.2.8.2. Market Share & Analysis

North India Cancer Treatment Drugs Market Outlook, 2022-2032

9.1. Market Size & Outlook

9.1.1. By Revenues (USD Million)

9.2. Market Share & Outlook

9.2.1. By Drug Class- Market Size & Forecast 2022-2032, USD Million

9.2.2. By Cancer Type- Market Size & Forecast 2022-2032, USD Million

9.2.3. By Dosage Form- Market Size & Forecast 2022-2032, USD Million

9.2.4. By End-Users- Market Size & Forecast 2022-2032, USD Million

9.2.5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million

9.2.6. By Region- Market Size & Forecast 2022-2032, USD Million

South India Cancer Treatment Drugs Market Outlook, 2022-2032

10.1. Market Size & Outlook

10.1.1. By Revenues (USD Million)

10.2. Market Share & Outlook

10.2.1. By Drug Class- Market Size & Forecast 2022-2032, USD Million

10.2.2. By Cancer Type- Market Size & Forecast 2022-2032, USD Million

10.2.3. By Dosage Form- Market Size & Forecast 2022-2032, USD Million

10.2.4. By End-Users- Market Size & Forecast 2022-2032, USD Million

10.2.5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million

10.2.6. By Region- Market Size & Forecast 2022-2032, USD Million

East India Cancer Treatment Drugs Market Outlook, 2022-2032

11.1. Market Size & Outlook

11.1.1. By Revenues (USD Million)

11.2. Market Share & Outlook

11.2.1. By Drug Class- Market Size & Forecast 2022-2032, USD Million

11.2.2. By Cancer Type- Market Size & Forecast 2022-2032, USD Million

11.2.3. By Dosage Form- Market Size & Forecast 2022-2032, USD Million

11.2.4. By End-Users- Market Size & Forecast 2022-2032, USD Million

11.2.5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million

11.2.6. By Region- Market Size & Forecast 2022-2032, USD Million

West India Cancer Treatment Drugs Market Outlook, 2022-2032

12.1. Market Size & Outlook

12.1.1. By Revenues (USD Million)

12.2. Market Share & Outlook

12.2.1. By Drug Class- Market Size & Forecast 2022-2032, USD Million

12.2.2. By Cancer Type- Market Size & Forecast 2022-2032, USD Million

12.2.3. By Dosage Form- Market Size & Forecast 2022-2032, USD Million

12.2.4. By End-Users- Market Size & Forecast 2022-2032, USD Million

12.2.5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million

12.2.6. By Region- Market Size & Forecast 2022-2032, USD Million

India Cancer Treatment Drugs Market Key Strategic Imperatives for Success & Growth
Competitive Outlook

14.1. Company Profiles

14.1.1. F. Hoffmann-La Roche AG

14.1.1.1. Business Description

14.1.1.2. Product Portfolio

14.1.1.3. Collaborations & Alliances

14.1.1.4. Recent Developments

14.1.1.5. Financial Details

14.1.1.6. Others

14.1.2. Bristol-Myers Squibb Company

14.1.2.1. Business Description

14.1.2.2. Product Portfolio

14.1.2.3. Collaborations & Alliances

14.1.2.4. Recent Developments

14.1.2.5. Financial Details

14.1.2.6. Others

14.1.3. AstraZeneca PLC

14.1.3.1. Business Description

14.1.3.2. Product Portfolio

14.1.3.3. Collaborations & Alliances

14.1.3.4. Recent Developments

14.1.3.5. Financial Details

14.1.3.6. Others

14.1.4. Novartis AG

14.1.4.1. Business Description

14.1.4.2. Product Portfolio

14.1.4.3. Collaborations & Alliances

14.1.4.4. Recent Developments

14.1.4.5. Financial Details

14.1.4.6. Others

14.1.5. Merck KGaA

14.1.5.1. Business Description

14.1.5.2. Product Portfolio

14.1.5.3. Collaborations & Alliances

14.1.5.4. Recent Developments

14.1.5.5. Financial Details

14.1.5.6. Others

14.1.6. Amgen Inc.

14.1.6.1. Business Description

14.1.6.2. Product Portfolio

14.1.6.3. Collaborations & Alliances

14.1.6.4. Recent Developments

14.1.6.5. Financial Details

14.1.6.6. Others

14.1.7. Bayer AG

14.1.7.1. Business Description

14.1.7.2. Product Portfolio

14.1.7.3. Collaborations & Alliances

14.1.7.4. Recent Developments

14.1.7.5. Financial Details

14.1.7.6. Others

14.1.8. Astellas Pharma Inc.

14.1.8.1. Business Description

14.1.8.2. Product Portfolio

14.1.8.3. Collaborations & Alliances

14.1.8.4. Recent Developments

14.1.8.5. Financial Details

14.1.8.6. Others

14.1.9. Cipla Limited

14.1.9.1. Business Description

14.1.9.2. Product Portfolio

14.1.9.3. Collaborations & Alliances

14.1.9.4. Recent Developments

14.1.9.5. Financial Details

14.1.9.6. Others

14.1.10. Natco Pharma Limited

14.1.10.1. Business Description

14.1.10.2. Product Portfolio

14.1.10.3. Collaborations & Alliances

14.1.10.4. Recent Developments

14.1.10.5. Financial Details

14.1.10.6. Others

Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *